IceCure Medical (NASDAQ:ICCM) Price Target Raised to $2.50

IceCure Medical (NASDAQ:ICCM) had its price target lifted by investment analysts at HC Wainwright from $2.00 to $2.50 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 150.00% from the company’s previous close.

ICCM has been the topic of a number of other research reports. Wall Street Zen downgraded IceCure Medical from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. Zacks Research cut shares of IceCure Medical from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Loop Capital set a $2.77 price objective on shares of IceCure Medical in a research report on Wednesday, August 13th. Brookline Capital Management reaffirmed a “buy” rating on shares of IceCure Medical in a research report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, IceCure Medical currently has a consensus rating of “Moderate Buy” and an average price target of $2.64.

IceCure Medical Stock Up 3.7%

Shares of IceCure Medical stock opened at $1.00 on Tuesday. The company has a quick ratio of 0.88, a current ratio of 1.18 and a debt-to-equity ratio of 0.02. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.66. The company has a market capitalization of $68.70 million, a P/E ratio of -6.25 and a beta of 0.31. The company has a 50 day moving average of $0.98 and a 200 day moving average of $1.04.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.12. The business had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $0.90 million. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. As a group, research analysts forecast that IceCure Medical will post -0.28 EPS for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.